AstraZeneca and Shenzhen University Health Science Center to collaborate on chronic kidney disease

摘要

AstraZeneca has entered a research collaboration with Shenzhen University Health Science Center. Under the agreement, the partners will undertake pre-clinical research focused on chronic kidney disease (CKD), which represents a large and growing unmetmedical need in China. In 2010, there were over 112 million kidney disease sufferers in China and this is expected to rise by 20% to more than 135 million by 2025.Under the terms of the agreement, scientists from Shenzhen University Health Science Center's Nephrology and Urology Center will work in collaboration with teams from AstraZeneca's Innovation Center China in Shanghai, bringing together complementary skills that will harness and foster medical innovation: Shenzhen University's academic and clinical capabilities and AstraZeneca's heritage in global research and drug discovery.